Current Report on Form 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 12, 2003
-------------
SANGUI BIOTECH INTERNATIONAL, INC.
----------------------------------
(Exact name of Registrant as specified in its charter)
Colorado
--------
(State or other jurisdiction of Incorporation or organization
000-21271 84-1330732
--------- ----------
(Commission File Number) (I.R.S. Employer Identification No.)
ALFRED-HERRHAUSEN-STR. 44, 58455 WITTEN, GERMANY
(Address of principal executive offices)(Zip Code)
011-49-2302-915-200
-------------------
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Item 7. Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release dated June 12, 2003
Item 9. Regulation FD Disclosure
On June 12, 2003 Sangui Biotech International, Inc. (the "Company")
issued a press release announcing its financial results to the first quarter
ended March 31, 2003. A copy of the earnings release is furnished as Exhibit
99.1 to this report.
The information in this Current Report on Form 8-K, including the
exhibit, is furnished under "Item 2. Management's Discussion and Analysis of
Financial Condition" in accordance with SEC Release No. 33-8216. Furthermore,
the information in this Current Report on Form 8-K, including the exhibit, shall
not be deemed to be incorporated by reference into the filings of the Company
under the Securities Act of 1933, as amended, or the Securities Exchange Act of
1934, as amended.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d)
of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the Undersigned, thereunto
duly authorized.
Sangui Biotech International, Inc.
(Registrant)
Date: July 10, 2003 /s/ Wolfgang Barnikol
--------------- ----------------------------
By: Wolfgang Barnikol
Its: President, CEO and CFO
INDEX TO EXHIBITS
Exhibit Number Exhibit
99.1 Press Release dated June 12, 2003*
* This exhibit is furnished to, but not filed with, the Commission by inclusion
herein.
SANGUI COST REDUCTION CONTINUED
(Witten, Germany, June 12, 2003) Sangui BioTech International, Inc. announced
today the filing with the U.S. Securities and Exchange Commission of its 10-QSB
Report for the nine month period ended March 31, 2003. At March 31, 200 the
Company had cash and cash equivalents plus available for sale securities
amounting to $1.8 million, down $2.2 million from the respective quarter of last
year. The Management of the Company believes that the available cash will be
sufficient to satisfy Sangui's requirements at least until March 31, 2004.
In the pursuit of the ongoing refocussing programme for cost reduction and fast
market entry, management has been able to reduce the Company's operating
expenses by 44% to $ 1.7 million in the nine month period of fiscal 2003,
compared to $ 3.0 million in the respective period of last fiscal year. The
average monthly net cash used in operating activities was approximately $
156.000 in the third quarter down from approximately $ 184.000 in the third
quarter of fiscal year 2002. At exchange rates as of March 31, 2002 the average
monthly net cash used in operating activities was approximately $ 130.000.